2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-144285
    CXCR4 antagonist 4 2761009-30-5 98%
    CXCR4 antagonist 4 is a potent, orally active CXCR4 antagonist (IC50=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC50=7 nM).
    CXCR4 antagonist 4
  • HY-144328
    STING agonist-10 2259308-69-3 98%
    STING agonist-10 (Compound 91) is a potent small molecule cyclic urea activator of STING with the EC50 of 2600 nM. Activation of STING is a highly promising approach in immunotherapy.
    STING agonist-10
  • HY-144329
    STING agonist-11 2259308-68-2 98%
    STING agonist-11 (Compound 92) is a potent small molecule cyclic urea activator of STING with EC50 of 18 nM. Activation of STING is a highly promising approach in immunotherapy.
    STING agonist-11
  • HY-14433A
    (S)-PF-462991 1149727-65-0 98%
    (S)-PF-462991 is a direct-acting S1P1,5 agonist.
    (S)-PF-462991
  • HY-144368
    CO delivery molecule 1 1972616-04-8 98%
    CO delivery molecule 1 (compound 4) localizes to the endoplasmic reticulum, mitochondria, and lysosomes. Subcellular localization of CO delivery molecule 1 results in CO-induced toxicity effects. Anti-inflammatory effects of CO delivery molecule 1, as measured by TNF-α suppression, occur at the nanomolar level in the absence of CO release, and are enhanced with visible-light-induced CO release.
    CO delivery molecule 1
  • HY-144371
    DHODH-IN-20 2639835-02-0 98%
    DHODH-IN-20 (Compound 133) is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-20 inhibits tumor growth. DHODH-IN-20 has the potential for the research of acute myelogenous leukemia.
    DHODH-IN-20
  • HY-144373
    IL-17 modulator 6 2725869-16-7 98%
    IL-17 modulator 6 (compound 61) is a potent Interleukin 17 (IL-17) modulator (pIC50=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the research of inflammatory and autoimmune diseases.
    IL-17 modulator 6
  • HY-144387
    Antibacterial agent 71 3033367-64-2 98%
    ient S. Tm and hyperpermeable Escherichia coli. The potencies against WT strains of E. coli, Acinetobacter baumannii, and Burkholderia cenocepacia are also improved considerably (up to >128-fold) with the outer-membrane permeabi
    Antibacterial agent 71
  • HY-144391
    Chitin synthase inhibitor 1 2763387-69-3 98%
    Chitin synthase inhibitor 1 is a potent and selective chitin synthase (CHS) inhibitor (IC50=0.12 mM). Chitin synthase inhibitor 1 has potent antifungal activity against drug-resistant fungi variants.
    Chitin synthase inhibitor 1
  • HY-144395
    HDAC6-IN-4 2709103-20-6 98%
    HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC50 value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity.
    HDAC6-IN-4
  • HY-144397
    LEO 134310 2089130-74-3 98%
    LEO 134310 is a selective, non-steroidal glucocorticoid receptor (GR) agonist optimized for topical research., LEO 134310 showed high affinity (EC50 of 14 nM) in a GR binding assay. LEO 134310 can be used for skin diseases.
    LEO 134310
  • HY-144618
    Antibacterial agent 74 1644387-48-3 98%
    Antibacterial agent 74 (compound 36) is an anti-Salmonella agent.
    Antibacterial agent 74
  • HY-144621
    Antibacterial agent 75 2765224-33-5 98%
    Antibacterial agent 75 (compound 24) is an antibacterial agent. Antibacterial agent 75 (compound 24) is able to re-sensitize VRSA to vancomycin.
    Antibacterial agent 75
  • HY-144639
    Carbonic anhydrase inhibitor 5 3033415-81-2 98%
    Carbonic anhydrase inhibitor 5 is a potent and selective human carbonic anhydrase (hCA) inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively.
    Carbonic anhydrase inhibitor 5
  • HY-144643
    CYP51/HDAC-IN-1 2502095-64-7 98%
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis.
    CYP51/HDAC-IN-1
  • HY-144672
    A2A receptor antagonist 2 2767206-20-0 98%
    A2A receptor antagonist 2 (Compound 57) is a potent, highly selective adenosine A2A receptor (A2AR) antagonist with an IC50 of 8.3 nM.
    A2A receptor antagonist 2
  • HY-144727
    Anti-inflammatory agent 11 63932-07-0 98%
    Anti-inflammatory agent 11 (compound 16) is a potent antimycobacterial and anti-inflammatory agent. Anti-inflammatory agent 11 inhibits Mtb H37Rv and M299 growth, with MIC50 (minimum inhibitory concentration 50%) of 1.3 and 6.9 μM, respectively. Anti-inflammatory agent 11 inhibits NO through the suppression of iNOS expression, and also inhibited the production of TNF-α and IL-1β. Anti-inflammatory agent 11 can be used for tuberculosis (TB) research.
    Anti-inflammatory agent 11
  • HY-144729
    Antibacterial agent 82 3032608-35-5 98%
    Antibacterial agent 82 (compound 7p) is an antibacterial agent.
    Antibacterial agent 82
  • HY-144730
    gp120-IN-1 5948-75-4 98%
    gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an IC50 of 2.2 µM and CC50 of 100.90 µM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells. gp120-IN-1 shows inhibition of gp120-mediated virus enter into cells.
    gp120-IN-1
  • HY-144731
    gp120-IN-2 123629-42-5 98%
    gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC50 of 7.5 µM and CC50 of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells.
    gp120-IN-2
Cat. No. Product Name / Synonyms Application Reactivity